Nivolumab, marketed as Opdivo (옵디보), is a medication used to Cancer immunotherapy. It is used as a first line treatment for inoperable or metastatic Melanoma in combination with Ipilimumab if the cancer does not have a mutation in BRAF, as a second-line treatment following treatment with ipilimumab and if the cancer has a mutation in BRAF, with a BRAF inhibitor, as a second-line treatment for squamous non-small cell lung cancer, and as a second-line treatment for renal cell carcinoma.

PD-1 target

Incoming Links #

Related Drug Classes (DrugClass 0) #

• PD-1 and PD-L1 inhibitors

Related Articles (Article 1) #

• Cancer immunotherapy

Suggested Pages #

• 0.294 Pembrolizumab
• 0.048 pVAC-Seq
• 0.024 January 12
• 0.024 November 7
• 0.023 Vectibix
• 0.023 Anti-GD2 antibodies
• 0.023 Erbitux
• 0.023 Atezolizumab
• 0.023 PD-L1
• 0.023 Vemurafenib
• More suggestions...